Idiotype‐pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

  title={Idiotype‐pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival},
  author={Martha Q. Lacy and Sumithra J. Mandrekar and Angela Dispenzieri and Suzanne R. Hayman and Shaji K. Kumar and Francis K. Buadi and David Dingli and Mark R. Litzow and Peter J. Wettstein and Douglas J. Padley and Brian F. Kabat and Dennis A Gastineau and Sundararajan Vincent Rajkumar and Morie A. Gertz},
  journal={American Journal of Hematology},
Vaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of a phase II trial of the immunotherapeutic, APC8020 (Mylovenge™), given after ASCT for MM. We compared the results with that of other patients with MM who underwent ASCT at Mayo Clinic during the same time period. Twenty‐seven patients were enrolled on the trial between July, 1998 and June, 2001, and the outcomes were compared to that of 124… 
Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.
Vaccines based on dendritic cells loaded with Id-protein are safe and induce specific immune response in multiple myeloma patients and suggest that the vaccination could stabilize the disease in approximately two-thirds of patients.
Immunotherapy strategies for multiple myeloma : the present & the future Review demonstrable after in vitro stimulation with autologous paraprotein
The CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation and optimization of dendritic cell-based immunotherapy in multiple myeloma are studied.
Immunotherapy for Multiple Myeloma
Recently, epoch-making immunotherapies, i.e., immunomodulatory drug-intensified monoclonal antibodies have been developed, and daratumumab combined with lenalidomide and chimeric antigen receptor T-cell therapy targeting B-cell maturation antigen was shown to improve prognosis even in advanced-stage MM patients.
Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities
The current role of transplantation and the progress that has been made in order to optimize the success of this therapy are reviewed and there is still much room for improvement.
Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma.
The promise of cellular therapy as treatment for multiple myeloma is highlighted by the observation that allogeneic transplantation results in durable remissions in a subset of patients and the lack of specificity of the alloreactive lymphocytes limits their therapeutic efficacy.
Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma
Findings strongly suggest that the immunotherapeutic strategies, including immune checkpoint inhibitors, therapeutic cancer vaccines and adoptive cellular therapies, are promising avenues of clinical research that may be most applicable in the minimal residual disease state following auto-HCT.
Multiple Myeloma and Dendritic Cell Vaccines
The present review provides the results of clinical trials dealing with the use of DC-based vaccines in multiple myeloma patients, and the potentials of improving the clinical effi cacy of this therapy are discussed.
Results of a Phase II clinical trial with Id-protein-loaded dendritic cell vaccine in multiple myeloma: encouraging or discouraging?
This study showed that Id-protein-loaded DC vaccines are safe and nontoxic and that they are able to induce immunity in some patients, and standardization of vaccination protocols appears to be the key to achieving a better clinical outcome.
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Clinical aspects of maintenance therapies that can be used post-ASCT to prolong remission duration are considered and questions which remain unanswered around the optimal use of currently available maintenance therapies are discussed.
Novel antigenic targets for immunotherapy in myeloma
  • Q. Yi
  • Biology, Medicine
  • 2009
This chapter will review the results of targeting idiotype proteins in preclinical and clinical studies of immunotherapies in MM conducted in the past 14 years and the potentials of novel antigenic targets for myeloma immunotherapy, either through active immunization or vaccination or by adoptive immunotherapy using antigen-specific monoclonal antibodies will be discussed in detail.


Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
  • A. Liso, K. Stockerl-Goldstein, R. Levy
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2000
Vaccination of multiple myeloma patients with idiotype‐pulsed dendritic cells: immunological and clinical aspects
Data indicate that immunotherapy with Id‐pulsed DCs in MM patients is feasible and safe, and DC generated from CD34+ progenitor cells can serve as a natural adjuvant for the induction of clinically relevant humoral and cellular idiotype‐specific immune responses in patients suffering from advanced MM.
Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy
The immune competence status of MM patients is still susceptible to specific immunization after high-dose chemotherapy and PBPC transplantation, and it remains to be determined whether generation of Id-specific immune responses can reduce the relapse rate of patients with minimal residual disease.
Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.
This study confirms an earlier report that patients with B-cell lymphoma can be induced to make a specific immune response against the Ig expressed by their own tumor and shows that the ability to make such an immune response is correlated with a more favorable clinical outcome.
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
ALC is correlated with clinical outcome and requires further study, and Multivariate analysis demonstrated day 15 ALC to be an independent prognostic indicator for OS and PFS rates for both groups of patients.
Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients.
Higher CD19(+) blood levels were positively associated with MM-patient survival at entry to the study, at year 2, and at relapse, which affirms the positive relationship between the quantitative status of the blood immune system in MM and survival.
Improved survival in multiple myeloma and the impact of novel therapies.
Improved outcome of patients with myeloma in recent years is demonstrated, both in the relapsed setting as well as at diagnosis, both from time of diagnosis and the time of relapse.
Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487).
The results add to the evidence that this malignant B cell disorder whether newly diagnosed or of longer duration, may be accompanied by an altered T cell repertoire characterized in part by expanded T cell clones.
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
In this pilot study, we investigated the ability of autologous dendritic cells pulsed ex vivo with tumor–specific idiotype protein to stimulate host antitumor immunity when infused as a vaccine. Four
Generation of anti‐idiotype immune responses following vaccination with idiotype‐protein pulsed dendritic cells in myeloma
Two patients with advanced refractory myeloma were treated with a series of four vaccinations using autologous idiotype‐protein pulsed dendritic cells combined with adjuvant GM‐CSF, and an idiotypes‐specific T‐cell proliferative response developed in both patients.